Sr. No Generic Name

Total Page:16

File Type:pdf, Size:1020Kb

Sr. No Generic Name Sheet1 Sr. No Generic Name 1 Aciclovir Eye Ointment BP 2 Alcaftadine and Ketorolac Tromethamine Ophthalmic Solution 3 Alcaftadine Ophthalmic Solution 0.25% w/v 4 Amikacin Sulphate Eye Drops 5 Ampicillin Sodium & Cloxacillin Sodium Intramammary Infusion (LC) BP (Vet) For Mastitis 6 Antazoline HCL Eye Drops 7 Antazoline plus Tetryzoline Eye Drops 8 Atropine Sulphate Ophthalmic Eye Ointment USP 9 Atropine Sulfate Ophthalmic Solution USP 0.01% w/v 10 Atropine Sulfate Ophthalmic Solution USP 0.5% 11 Atropine Sulphate & Prednisolone Eye Drops 12 Atropine Sulphate & Prednisolone Eye Drops 13 Azelastine 0.05% w/v Eye Drops 14 Azithromycin 0.3% Eye Drops 15 Azithromycin Eye Drops 1 % W/V 16 Azithromycin Ophthalmic Ointment 1%W/W 17 Bepotastine Besilate Ophthalmic Solution 1.5% w/v 18 Besifloxacin Ophthalmic Suspension 0.6% W/V 19 Betamethasone & Neomycin Eye /Ear/Nasal Drop 20 Betamethasone Sodium Phosphate Eye /Ear/Nasal/ Drops 21 Betaxolol Ophthalmic Solution USP 22 Bimatoprost & Timolol Maleate Ophthalmic Solution 23 Bimatoprost Ophthalmic Solution 0.01% 24 Bimatoprost Ophthalmic Solution 0.03%W/V 25 Boric Acid & Zinc Sulphate Eye Drop 26 Boric Acid, Zinc Sulphate & Sodium Borate Eye Drops 27 Brimonidine Tartrate & Timolol Maleate Ophthalmic Solution 0.2% W/V 28 Brimonidine Tartrate 0.2% w/v, Polyvinyl Alcohol 1.4% w/v Eye Drops 29 Brimonidine Tartrate Ophthalmic Solution 0.1% W/V 30 Brimonidine Tartrate Ophthalmic Solution 0.15% W/V 31 Brimonidine Tartrate Ophthalmic Solution 0.2% W/V 32 Brinzolamide Ophthalmic Suspension USP 1.0% W/V 33 Bromfenac Ophthalmic Solution 0.09% W/V 34 Carbomer 0.2% W/W Eye Gel 35 Carboxymethylcellulose Sodium Eye Drops 36 Carmellose Sodium Eye Drops BP 1% 37 Carmellose Sodium Eye Drops BP 0.5% 38 Carmellose Sodium Eye Drops BP 0.5% 39 Carmellose Sodium Eye Drops BP 0.5% 40 Cefoperazone Sodium Intrammary Suspension 41 Cefuroxime Sodium Intramammary Infusions 42 Cephalexin & Kanamycin Sulphate Intramammry Suspension 43 Cephalexin Neomycin Sulphate & Prednisolone Infusion 44 Chloramphenicol Eye Ointment USP 0.5% 45 Chloramphenicol Ophthalmic Ointment USP 1% W/W 46 Chloramphenicol Ophthalmic Solution USP 0.25% w/v 47 Chloramphenicol Ophthalmic Solution USP 0.4% w/v 48 Chloramphenicol Ophthalmic Solution USP 1% W/V 49 Chloramphenicol Sodium Succinate Intramammary Infusion 50 Chloramphrenicol & Hydrocortisone Eye Ointment 51 Ciprofloxacin & Dexamethasone Eye /Ear Drops 52 Ciprofloxacin & Dexamethasone Ophthalmic Suspension 53 Ciprofloxacin Ophthalmic Ointment USP 54 Ciprofloxacin Ophthalmic Solution USP 55 Clobetasone Butyrate Eye Drops 56 Cloxacillin Sodium & Colistin Sulphate Intrammammary Infusion (Vet) 57 Cloxacillin Sodium Intrammammary Infusion (LC) BP (Vet) For Mastitis Page 1 58 Cromolyn Sodium Ophthalmic Solution USP Sheet1 59 Cromolyn Sodium Ophthalmic Solution USP 60 Cyclopentolate Hcl Ophthalmic Solution USP 1% W/V 61 Cyclopentolate Hydrochloride & Dexamethasone Sodium Phosphate Ophthalmic Solution 62 Cyclosporin Ophthalmic Ointment 2mg/Gm 63 Cyclosporine Eye Drop BP 0.1% 64 Cyclosporine Eye Drops BP 0.05% 65 Dexamethasobe Sodium Metasulphobenzoate 0.116% & Soframycin 1% w/v Eye Drops 66 Dexamethasone Ophthalmic Suspension USP 67 Dexamethasone Sodium Phosphate & Chloramphenicol Eye Drops 68 Dexamethasone Sodium Phosphate Ophthalmic Solution USP 69 Dexamethasone Sodium Phosphate Ophthalmic Solution USP 70 Dexamethasone Sodium Phosphate Ophthalmic Solution USP 71 Dexpenthenol Ophthalmic Gel 5% W/W 72 Diclofenac Sodium 1mg & Gentamicin Sulphate 3mg Eye Drosp 73 Diclofenac Sodium Ophthalmic Solution 74 Diclofenac Sodium Ophthalmic Solution 75 Dinoprostone 0.5 Mg / 3 Gm Gel 76 Dipyridamol Ophthalmic Solution 0.008% w/v 77 Dorzolamide Eye Drops BP 2.0%W/V 78 Dorzolamide Hydrochloride & Timolol Maleate Eye Drops 79 Dorzolamide, Timolol & Brimonidine Tartrate Ophthalmic Solution 80 Epinastine 0.05% Eye Drops 81 Erythromycin Ophthalmic Ointment USP 82 Eye Drops Of Phenylephrine Hcl. & NaphazolineHcl 83 Fluconazole Eye Drops 84 Fluorometholone & Neomycin Sulphate Ophthalmic Suspension 85 Flurbiprofen & Gatifloxacin Eye Drops 86 Flurbiprofen Sodium Ophthalmic Solution USP 87 Flurometholone Eye Drops IP 0.1% 88 Flurometholone Eye Drops IP 0.25% 89 Ganciclovir Ophthalmic Gel 0.15%W/W 90 Gatifloxacin & Dexamethasone Ophthalmic Solution 91 Gatifloxacin & Ketorolac Tromethamine Ophthalmic Solution 92 Gatifloxacin & Loteperdnol Ophthalmic Suspension 93 Gatifloxacin & Prednisolone Acetate Ophthalmic Suspension 94 Gatifloxacin Eye Drops 0.3%W/V 95 Gatifloxacin Eye Drops 0.5%W/V 96 Gatifloxacin Eye Drops 0.5%W/V 97 Gatifloxacin Ophthalmic Ointment 98 Gentamicin & Dexamethasone Sodium Phosphate Eye Drops 99 Gentamicin Eye/Ear Drops 0.3% w/v 100 Gentamicin Sulphate Ophthalmic Ointment U.S.P 101 Gentamicin Sulphate Ophthalmic Solution U.S.P 102 Gentamycin Sulfate & Dexamethasone Sodium Phosphate Eye Drops 103 Glycerin & Carboxymethylcellulose Sodium Eye Drops 104 Homatropine Hydrobromide Ophthalmic Solution USP 105 Hydrocortisone Acetate 1% & Sulphacetamide Sodium 10% w/v Eye Drops 106 Hydrocortisone Acetate Eye Ointment IP 0.5% W/W 107 Hydrocortisone Acetate Eye Ointment USP 0.5% W/W 108 Hydrocortisone Acetate Eye Ointment USP 1% 109 Hydrocortisone Acetate Ophthalmic Suspension USP 0.5% 110 Hydrocotidone Acetate 1% & Gentamicin Sulphate (Eq. To Gentamicin base ) 0.3% w/v Eye Drops 111 Hydroxypropyl Methyl Cellulose (Hypromellose) Ophthalmic Solution USP 0.3% 112 Hydroxypropyl Methyl Cellulose (Hypromellose) Ophthalmic Solution USP 0.7% 113 Hydroxypropyl Methyl Cellulose (Hypromellose) Ophthalmic Solution USP 2% 114 Hydroxypropyl Methyl Cellulose (Hypromellose) Ophthalmic Solution USP 0.5% Page 2 Hydroxypropyl Methyl Cellulose 0.7% w/v, Borax 0.19%w/v,Sheet1 Boric Acid 0.19% w/v, Sodium Chloride 0.45% w/v, Potassium 115 Chloride 0.37% w/v, Benzalkonium Chloride 0.02% w/v Eye Drops 116 Hydroxypropyl Methyl Cellulose Ophthalmic Gel 0.3% 117 Hypromellose + Glycerine +Dextran 70 Ophthalmic Solution 118 Idoxuridine 0.1% Eye Drops 119 Idoxuridine 0.1% Eye Ointment 120 Itraconazole Ophthalmic Ointment 121 Itraconazole Ophthalmic Suspension 122 Ketoconazole 2% w/v Eye Drops 123 Ketorolac 0.5% with HPMC Eye Drops 124 Ketorolac Tromethamine & Ofloxacin Ophthalmic Solution 125 Ketorolac Tromethamine 0.4% w/v, Fluorometholone 0.1% w/v & Polyvenyl Alcohol 1.4% w/v Eye Drops 126 Ketorolac Tromethamine 4mg & Gatifloxacin 3mg Eye Drops 127 Ketorolac Tromethamine Ophthalmic Solution 128 Ketorolac Tromethamine Ophthalmic Solution 0.4% 129 Ketotifen 0.5% w/v Eye Drops 130 Latanoprost & Timolol Maleate Ophthalmic Solution 131 Latanoprost Ophthalmic Solution 0.005% USP 132 Levobunolol 0.5% Eye Drops 133 Levofloxacin 0.5% Eye Drops 134 Levofloxacin Ophthalmic Solution 1.5% W/V 135 Lidocaine Hydrochloride Jelly USP 2% Sterile 136 Lidocaine Hydrochloride Ophthalmic Gel 3.5% W/W 137 Lignocaine Eye Drops 138 Loteprednol Etabonate & Moxifloxacin Ophthalmic Suspension 139 Loteprednol Etabonate Ophthalmic Ointment 0.5%W/W 140 Loteprednol Etabonate Ophthalmic Suspension (0.5% W/V) 141 Loteprednol Etabonate Ophthalmic Suspension 0.2% 142 Methyl Prednisolone Acetate 0.1% w/w Eye Ointment 143 Moxifloxacin & Bromfenac Ophthalmic Solution 144 Moxifloxacin & Dexamethasone Eye Drops 145 Moxifloxacin & Dexamethasone Ophthalmic Solution 146 Moxifloxacin & Difluprednate Ophthalmic Emulsion 147 Moxifloxacin & Prednisolone Acetate Ophthalmic Solution 148 Moxifloxacin and Ketorolac Tromethamine Ophthalmic Solution 149 Moxifloxacin Hydrochloride Ophthalmic Ointment 150 Moxifloxacin Ophthalmic Solution USP 151 Moxifloxacin Ophthalmic Solution USP 152 Naltrexone Hydrochloride Solution 153 Naphazoline Hydrochloride ,Phenylephrine Hydrochloride & Sodium CarboxymethylCelluose Ophthalmic Solution 154 Naphazoline Hydrochloride ,Zinc Sulphate & Chlorpheniramine Maleate Ophthalmic Solution 155 Naphazoline Hydrochloride Ophthalmic Solution USP 0.012%W/V 156 Naphazoline Hydrochloride, Zinc Sulphate, Chlorpheniramine Maleate and HPMC Ophthalmic Solution 157 Natamycin Ophthalmic Suspension USP 5% 158 Nedocromil Sodium 2.0% Eye Drops 159 Neomycin Sulfate and Dexamethasone Sodium Phosphate Eye/Ear Drops 160 Neomycin Sulphate & Betamethasone Sodium Phosphate Ophthalmic Solution USP 161 Neomycin Sulphate & Dexamethasone Sodium Phosphate Ophthalmic Solution USP 162 Neomycin Sulphate & Dexamethasone Sodium Phosphate Ophthalmic Solution USP 163 Neomycin Sulphate ,Boric Acid & Dexamethasone Sodium Phosphate Eye/Ear Drops 164 Neomycin, Hydrocortisone & Bacitracin Zinc Eye Ointment 165 Neomycin, Polymyxin B Sulfate & Dexamethasone Ophthalmic Ointment USP 166 Neomycin, Polymyxin B Sulfate & Dexamethasone Ophthalmic Ointment USP 167 Neomycin, Polymyxin B Sulfate & Dexamethasone Ophthalmic Suspension USP 168 Nepafenac Ophthalmic Suspension 0.1%W/V 169 Norfloxacin USP Ophthalmic Solution USP 170 Ofloxacin 0.3% w/v & Ketorolac 0.5% w/v Eye Drops 171 Ofloxacin 3mg & Prednisolone Acetate 10mg Eye Drops Page 3 172 Ofloxacin and Prednisolone Sodium Phosphate OphthalmicSheet1 Solution 173 Ofloxacin Eye Ointment 0.3% W/W 174 Ofloxacin Eye/Ear Drops 175 Ofloxacin Ophthalmic Solution USP 176 Ofloxacin& Dexamethasone Eye Drops USP 177 Olopatadine & Ketorolac Tromethamine Ophthalmic Solution 178 Olopatadine & Ketorolac Tromethamine Ophthalmic Solution 179 Olopatadine Hydrocloride Ophthalmic Solution USP 180 Olopatadine Hydrocloride Ophthalmic Solution USP 181 Oxytetracycline Hydrochloride & Polymyxin-B Sulfate Ophthalmic Ointment USP 182 Oxytetracycline Ophthalmic Ointment 183 Phenylephrine
Recommended publications
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management
    Journal of Clinical Medicine Review Conceptual Model for Using Imidazoline Derivative Solutions in Pulpal Management Robert S. Jones Division of Pediatric Dentistry, Department of Developmental & Surgical Sciences, School of Dentistry, University of Minnesota, Minneapolis, MN 55455, USA; [email protected] Abstract: Alpha-adrenergic agonists, such as the Imidazoline derivatives (ImDs) of oxymetazoline and xylometazoline, are highly effective hemostatic agents. ImDs have not been widely used in dentistry but their use in medicine, specifically in ophthalmology and otolaryngology, warrants consideration for pulpal hemostasis. This review presents dental healthcare professionals with an overview of ImDs in medicine. ImD solutions have the potential to be more effective and biocompatible than existing topical hemostatic compounds in pulpal management. Through a comprehensive analysis of the pharmacology of ImDs and the microphysiology of hemostasis regulation in oral tissues, a conceptual model of pulpal management by ImD solutions is presented. Keywords: hemostasis; alpha-adrenergic agonists; imidazoline; oxymetazoline; nasal; dental pulp; mucosa; apexogenesis; pulpotomy; direct pulp cap; dentistry 1. Overview Citation: Jones, R.S. Conceptual The purpose of this review is to formulate a conceptual model on the potential man- Model for Using Imidazoline agement of pulpal tissue by imidazoline derivatives (ImDs) based on a review of the Derivative Solutions in Pulpal literature that examines the hemostatic properties and mechanistic actions of these com- Management. J. Clin. Med. 2021, 10, 1212. https://doi.org/10.3390/ pounds in other human tissues. Commercial ImDs are formulated in solution with an- jcm10061212 timicrobial preservatives in order to act as ‘parenteral topical agents’ and used to manage ophthalmic inflammation, nasal congestion, and to control bleeding during otolaryngology Academic Editor: Rosalia surgery [1,2].
    [Show full text]
  • FEEVA / FVE Position for Improving Availability of Medicines Bringing Added Clinical Benefit for Treatment in Horses
    Brussels, 9 March 2017 FVE/017/doc/029 FEEVA / FVE position for improving availability of medicines bringing added clinical benefit for treatment in horses Request to include tenoic acid, phenylbutazone for systemic use and tetracaine, tetryzoline, synephrine, rifamycine, polymyxine B for ophthalmic use on the list of substances bringing added clinical benefit for treatment in horses. The therapeutic arsenal of medicines for horses (food-producing species in the European Union) is limited. Considering this, the EU has provided specific regulations for the horse industry to derogate from the principle that food animals can only be treated with active substances for which a Maximum Limit of Residues (MLR) has been established. Therefore, Regulation (EC) No 1950/2006 of 13 December 2006 in accordance with Directive 2001/82 / EC of the European Parliament and the Council on the Community code relating to veterinary medicinal, establishes a list of essential substances and substances bringing added clinical benefit for the treatment of horses. The ‘essential and clinical benefit list’ in Regulation 1950/2006 allows the treatment of horses whose meat or products are intended for human consumption with listed substances. Substances included in this list are considered as essential for the treatment of equine diseases and/or present additional clinical benefit, even if they don't have a defined MRL. In these cases, a waiting period of six months must be respected before sending treated animals for human consumption. According to the legislation substances bringing added clinical benefit may be used, for the specific disease conditions, based on improved efficacy or safety or a major contribution to treatment compared to other products authorized for Equidae.
    [Show full text]
  • Discovery of Novel Imidazolines and Imidazoles As Selective TAAR1
    Discovery of Novel Imidazolines and Imidazoles as Selective TAAR1 Partial Agonists for the Treatment of Psychiatric Disorders Giuseppe Cecere, pRED, Discovery Chemistry F. Hoffmann-La Roche AG, Basel, Switzerland Biological Rationale Trace amines are known for four decades Trace Amines - phenylethylamine p- tyramine p- octopamine tryptamine (PEA) Biogenic Amines dopamine norepinephrine serotonin ( DA) (NE) (5-HT) • Structurally related to classical biogenic amine neurotransmitters (DA, NE, 5-HT) • Co-localised & released with biogenic amines in same cells and vesicles • Low concentrations in CNS, rapidly catabolized by monoamine oxidase (MAO) • Dysregulation linked to psychiatric disorders such as schizophrenia & 2 depression Trace Amines Metabolism 3 Biological Rationale Trace Amine-Associated Receptors (TAARs) p-Tyramine extracellular TAAR1 Discrete family of GPCR’s Subtypes TAAR1-TAAR9 known intracellular Gs Structural similarity with the rhodopsin and adrenergic receptor superfamily adenylate Activation of the TAAR1 cyclase receptor leads to cAMP elevation of intracellular cAMP levels • First discovered in 2001 (Borowsky & Bunzow); characterised and classified at Roche in 2004 • Trace amines are endogenous ligands of TAAR1 • TAAR1 is expressed throughout the limbic and monoaminergic system in the brain Borowsky, B. et al., PNAS 2001, 98, 8966; Bunzow, J. R. et al., Mol. Pharmacol. 2001, 60, 1181. Lindemann L, Hoener MC, Trends Pharmacol Sci 2005, 26, 274. 4 Biological Rationale Electrical activity of dopaminergic neurons + p-tyramine
    [Show full text]
  • Test Summary Sheet For
    Test Summary Sheet for: 8054B Postmortem, Expanded with NPS, Blood (Forensic) The following test codes are contained in this document: 1. 8054B Postmortem, Expanded with NPS, Blood (Forensic) 2. 50000B Acetaminophen Confirmation, Blood (Forensic) 3. 52250B Alcohols and Acetone Confirmation, Blood (Forensic) 4. 52143B Alfentanil and Sufentanil Confirmation, Blood (Forensic) 5. 52168B Amitriptyline and Metabolite Confirmation, Blood (Forensic) 6. 52239B Amoxapine Confirmation, Blood (Forensic) 7. 52485B Amphetamines Confirmation, Blood (Forensic) 8. 52416B Aripiprazole Confirmation, Blood (Forensic) 9. 52007B Atomoxetine Confirmation, Blood (Forensic) 10. 50011B Barbiturates Confirmation, Blood (Forensic) 11. 52365B Bath Salts Confirmation, Blood (Forensic) 12. 52367B Bath Salts Confirmation, Blood (Forensic) 13. 50012B Benzodiazepines Confirmation, Blood (Forensic) 14. 52443B Benztropine Confirmation, Blood (Forensic) 15. 52245B Brompheniramine Confirmation, Blood (Forensic) 16. 52011B Bupivacaine Confirmation, Blood (Forensic) 17. 52012B Bupropion and Metabolite Confirmation, Blood (Forensic) 18. 52444B Buspirone Confirmation, Blood (Forensic) 19. 52198B Cannabinoids Confirmation, Blood (Forensic) 20. 52015B Carbamazepine and Metabolite Confirmation, Blood (Forensic) 21. 52017B Carisoprodol and Metabolite Confirmation, Blood (Forensic) 22. 52440B Chlorpheniramine Confirmation, Blood (Forensic) 23. 52272B Chlorpromazine Confirmation, Blood (Forensic) 24. 52482B Citalopram Confirmation, Blood (Forensic) 25. 52274B Clomipramine and Metabolite
    [Show full text]
  • Pharmaceuticals
    Tel. +27‐51‐401‐3344 www.liquidtech.co.za FAX +27‐51‐401‐9069 Analysis: Qualitative Package: Pharmaceuticals Aceclidine Bupivacaine Dihydroergotamine Aceprometazine Bupranolol Dilazep Aciclovir Buprenorphine Diltiazem Ajmaline Buspirone Diphenhydramine Aldicarb Sulphone Butaperazine Dipyridamole Aldicarb‐sulfoxide Caffeine Disopyramide alpha‐Hydroxyalprazolam Carazolol Dixyrazine alpha‐Hydroxytriazolam Carbamazepine Doxapram Alprazolam Carbinoxamine Doxepin Alprenolol Carbuterol Ecgoninemethylester Amantadine Carteolol Embutramide Amiloride Carvedilol Enalapril Aminoclonazepam 7‐ Celiprolol Ephedrine Aminoflunitrazepam 7‐ Cetirizine Eprosartan Aminonitrazepam 7‐ Chlorcyclizine Esmolol Aminophenazone Chlordiazepoxide Estazolam Aminopromazine Chlorphenethiazine Ethenzamide Amiodarone Chlorpheniramine Felodipine Amiphenazole Chlorpromazine Fenarimol Amitriptylin Chlorprothixene Fendiline Amoxicillin Cilazapril Fenetylline Amphetamine Cinnarizine Fenfluramine Apomorphine Citalopram Fentanyl Aprinidine Clemastine Fexofenadine Atenolol Clenbuterol Flecainide Atorvastatin Clobazam Fluconazole Atropine Clobutinol Flufenoxuron Aztreonam Clomethiazole Flunitrazepam Befunolol Clomipramine Fluoxetine Bendiacarb Clonazepam Fluphenazine Benzatropine Clonidine Flurazepam Benzocaine Clozapine Fluvoxamine Benzoctamine Cocaine Gabapentin Benzoylecgonine Codeine Gallopamil Berberine Coumatetralyl Glibenclamide Betaxolol Cyclicine Glibornuride Bezafibrate Demeton‐S‐methyl Glimepiride Biperiden Desalkylflurazepam Glipizide Bisoprolol Desipramine Gliquidone
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • IV. CONTENTS of the 10Th EDITION
    EUROPEAN PHARMACOPOEIA 10.0 Contents of the 10th Edition IV. CONTENTS OF THE 10th EDITION The 10th Editionconsistsofnewtextsaswellasallcurrenttextsfromthe9th Edition, some of which have been revised or corrected. Lists of the monographs and general chapters that, for the 10th Edition, are new, revised or corrected, or have had their titles or chapter numbers changed, are given below. Theversiondate(forexample01/2020foratextthatisneworrevisedforthe10th Edition), completed by ‘corrected X.X’ if a corrected version of the text has subsequently been published in Supplement X.X, and the reference number (4 digits for monographs and 5 digits for general chapters) are specified above the title of each monograph and general chapter. The version date, completed by ‘corrected X.X’ if appropriate, makes it possible to identify the successive versions of texts in different editions. ThevolumeinwhichthecurrentversionwasfirstpublishedisstatedintheKnowledgedatabaseontheEDQMwebsite. As of the 10th Edition, all revised or corrected parts of a text are indicated by vertical lines in the margin and horizontal lines in themarginindicatewherepartsofatexthavebeendeleted.Linesinthemarginthatwerepresentinrevisedorcorrectedtexts in the previous edition are deleted with each new edition. Corrected texts are to be taken into account as soon as possible and not later than the end of the month following the month of publication of the volume. New and revised texts are to be taken into account not later than the implementation date. A barcode is included at the start of each text, providing a link to further information on the text (e.g. the Knowledge database) for smartphones and tablets with a camera and a barcode reader app. In addition to corrections made to individual texts, the following decisions and systematic modifications have been made to the texts of the European Pharmacopoeia for the 10th Edition.
    [Show full text]
  • Hispanic Use of Alternative Medicine As Demonstrated in Internet Searches
    University of Texas Rio Grande Valley ScholarWorks @ UTRGV Communication Faculty Publications and Presentations College of Liberal Arts 2017 Hispanic Use of Alternative Medicine as Demonstrated in Internet Searches Elad Yom-Tov Microsoft William F. Strong The University of Texas Rio Grande Valley Lupita Rodriguez Strong The University of Texas Rio Grande Valley Follow this and additional works at: https://scholarworks.utrgv.edu/com_fac Part of the Communication Commons, Diseases Commons, and the Health Information Technology Commons Recommended Citation Yom-Tov, E., Strong, W., & Strong, L. (2017). Hispanic Use of Alternative Medicine as Demonstrated in Internet Searches. Health Behavior And Policy Review, 4(5), 503-510. https://doi.org/10.14485/ hbpr.4.5.10 This Article is brought to you for free and open access by the College of Liberal Arts at ScholarWorks @ UTRGV. It has been accepted for inclusion in Communication Faculty Publications and Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact [email protected], [email protected]. Hispanic Use of Alternative Medicine as Demonstrated in Internet Searches Elad Yom-Tov, PhD William F. Strong, PhD Lupita Rodriguez Strong, MA Objective: We investigated how cultural shifts occur with respect to the use of traditional medi- cine for influenza-like illness (ILI) within the Latino population near the US-Mexico border.Meth - ods: We extracted searches of ILI treatments (modern, traditional western, and traditional His- panic) to the Bing search engine from 5 US states near the US-Mexico border. The incidence of these searches was correlated with county-level demographic data and ILI incidence.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]